Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-02

Clinical Trial Update: A Study of Abemaciclib in Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Results from a Phase 2 study of abemaciclib in recurrent glioblastoma have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Glioblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-02